Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
Titel:
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
Auteur:
Liu, Xiaofan Zhou, Hu Hu, Yu Yin, Jie Li, Junmin Chen, Wenming Huang, Ruibin Gong, Yuping Luo, Chengwei Mei, Heng Ding, Bingjie Gu, Chengyuan Sun, Huiping Leng, Yun Ji, Dexiang Li, Yan Yin, Hongyan Shi, Haiyan Chen, Keyan Wang, Jian Fan, Songhua Su, Weiguo Yang, Renchi